Efficacy of pemetrexed plus platinum doublet chemotherapy as first-line treatment for advanced nonsquamous non-small-cell-lung cancer: a systematic review and meta-analysis

Por Xiao, Huai-Qing, Tian, Rong-Hua, Zhang, Zhi-Hao, Du, Kai-Qi, Ni, Yi-Ming
Publicado no Onco Targets Ther (2016)

Clonally‐related primary ALK rearranged adenocarcinoma and associated metastatic lesions

Por Zhu, You‐cai, Deng, Yun‐te, Wang, Wen‐xian, Xu, Chun‐wei, Zhuang, Wu, Du, Kai‐qi
Publicado no Thorac Cancer (2018)

CEP72‐ROS1: A novel ROS1 oncogenic fusion variant in lung adenocarcinoma identified by next‐generation sequencing

Por Zhu, You‐cai, Zhou, Yue‐fen, Wang, Wen‐xian, Xu, Chun‐wei, Zhuang, Wu, Du, Kai‐qi, Chen, Gang
Publicado no Thorac Cancer (2018)

Dual drive coexistence of EML4‐ALK and TPM3‐ROS1 fusion in advanced lung adenocarcinoma

Por Zhu, You‐cai, Liao, Xing‐hui, Wang, Wen‐xian, Xu, Chun‐wei, Zhuang, Wu, Wei, Jian‐guo, Du, Kai‐qi
Publicado no Thorac Cancer (2017)

Hemangioma of the Rib: A Rare Case Report and Literature Review

Por Zhu, You-cai, Lin, Xue-ping, Lu, Yan, Wang, Wen-xian, Du, Kai-qi, Ye, Xiao-qian, Zong, Chong, Xu, Chun-wei
Publicado no Open Med (Wars) (2017)

Lung cancer with concurrent EGFR mutation and ROS1 rearrangement: a case report and review of the literature

Por Zhu, You-cai, Xu, Chun-wei, Ye, Xiao-qian, Yin, Man-xiang, Zhang, Jin-xian, Du, Kai-qi, Zhang, Zhi-hao, Hu, Jian
Publicado no Onco Targets Ther (2016)

Intestinal metastasis from primary ROS1-positive lung adenocarcinoma cancer patients responding to crizotinib

Por Chen, Hua-fei, Zhang, Qu-xia, Zhu, You-cai, Du, Kai-qi, Li, Xiao-feng, Wu, Li-xin, Wang, Wen-xian, Xu, Chun-wei
Publicado no Onco Targets Ther (2018)

A novel co-existing ZCCHC8-ROS1 and de-novo MET amplification dual driver in advanced lung adenocarcinoma with a good response to crizotinib

Por Zhu, You-cai, Wang, Wen-xian, Xu, Chun-wei, Zhuang, Wu, Song, Zheng-bo, Du, Kai-qi, Chen, Gang, Lv, Tang-feng, Song, Yong
Publicado no Cancer Biol Ther (2018)

Clinicopathological features and clinical efficacy of crizotinib in Chinese patients with ROS1-positive non-small cell lung cancer

Por Zhu, You-Cai, Zhang, Xin-Gen, Lin, Xue-Ping, Wang, Wen-Xian, Li, Xiao-Feng, Wu, Li-Xin, Chen, Hua-Fei, Xu, Chun-Wei, Du, Kai-Qi
Publicado no Oncol Lett (2019)

Patients harboring ALK rearrangement adenocarcinoma after acquired resistance to crizotinib and transformation to small-cell lung cancer: a case report

Por Zhu, You-cai, Liao, Xing-hui, Wang, Wen-xian, Xu, Chun-wei, Zhuang, Wu, Zhong, Li-hua, Du, Kai-qi, Chen, Yan-ping, Chen, Gang, Fang, Mei-yu
Publicado no Onco Targets Ther (2017)

Comparison of the c‐MET gene amplification between primary tumor and metastatic lymph nodes in non‐small cell lung cancer

Por Xu, Chun‐wei, Wang, Wen‐xian, Wu, Mei‐juan, Zhu, You‐cai, Zhuang, Wu, Lin, Gen, Du, Kai‐qi, Huang, Yun‐jian, Chen, Yan‐ping, Chen, Gang, Fang, Mei‐yu
Publicado no Thorac Cancer (2017)

Patient harboring a novel PIK3CA point mutation after acquired resistance to crizotinib in an adenocarcinoma with ROS1 rearrangement: A case report and literature review

Por Xu, Chun‐wei, Wang, Wen‐xian, Huang, Rong‐fang, He, Cheng, Liao, Xing‐hui, Zhu, You‐cai, Du, Kai‐qi, Zhuang, Wu, Chen, Yan‐ping, Chen, Gang, Fang, Mei‐yu
Publicado no Thorac Cancer (2017)

Concurrent ROS1 gene rearrangement and KRAS mutation in lung adenocarcinoma: A case report and literature review

Por Zhu, You‐cai, Lin, Xue‐ping, Li, Xiao‐feng, Wu, Li‐xin, Chen, Hua‐fei, Wang, Wen‐xian, Xu, Chun‐wei, Shen, Jian‐fa, Wei, Jian‐guo, Du, Kai‐qi
Publicado no Thorac Cancer (2017)

Lung adenocarcinoma patient with an EGFR kinase domain duplication (KDD) and the response to icotinib

Por Zhu, You-Cai, Wang, Wen-Xian, Xu, Chun-Wei, Tan, Qing-He, Li, Jian-Ying, Zhuang, Wu, Song, Zheng-Bo, Du, Kai-Qi, Chen, Gang, Lv, Tang-Feng, Song, Yong
Publicado no J Thorac Dis (2018)